Cellectis SAALCLS:PAR

17.32
0.47 / 2.79%
20.29k
35.83 %
1.24
Latest price in EURToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 12 2016 09:27 GMT.

Directors & officers

 NameTitleCompensationAgeOfficer
since
 
AndreChoulika
Chairman of the Board, Chief Executive Officer
328.40k EUR
--
2000
Dr. Andre Choulika is one of the founders of Cellectis SA and has been Chairman of the Board and Chief Executive Officer since 2000. He has also been President of Calyxt (previously Cellectis plant sciences) since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. He has also served on the Boards of Directors of several biotechnology companies. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. Dr. Choulika also has management training from the HEC (Challenge +).
 
ThierryMoulin
Chief Financial Officer
--
--
2014
 
MathieuSimon
Chief Operating Officer, Executive Vice President, Director
--
--
2012
 
DavidSourdive
Executive Vice President-Corporate Development, Director
248.80k EUR
--
2008
 
PhilippeDuchateau
Chief Scientific Officer
--
--
2004
 
LaurentArthaud
Independent Director
--
--
2011
 
PierreBastid
Independent Director
--
--
2011
 
AlainGodard
Independent Director
35.88k EUR
--
2007
 
Jean-MarieMessier
Independent Director
--
--
--
 
AnnickSchwebig
Independent Director
--
--
2011
View all 10 directors & officersOfficers and Directors data as of Feb 07 2016

Director dealings

Mouseover chart for details.
There are no recent director transactions available.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.